144 ·Filed Sep 14, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 2/10
Horizonimmediate Processed17d 21h ago SEC0001950047-26-009440
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-motivated sale tied to RSU vesting under a 10b5-1 plan. No material insider signal. Monitor for any unplanned insider sales ahead of upcoming catalysts (e.g., clinical trial readouts).

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+5d ⚠ clustered
PHVS ▼ -7.51% at T+5d
NEUTRAL call ✗ call lost -7.51% · α vs SPY -9.63% · entry $38.06 → $35.20
Next anchor: T+20d in 10d
Latest observation: T+10 -25.74% FF3 residual α
Entry anchored
Sep 14, 04:48 PM ET
via 1-min bar
T+1d
-1.34%
call -1.34% · α -0.90%
$37.55
settled 17d ago
T+5d
-7.51%
call -7.51% · α -9.63%
$35.20
settled 11d ago
T+20d
—
call — · α —
—
in 10d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Director Berndt Modig filed a Form 144 to sell 2,291 common shares (approx. $87K) on September 14, 2026. The shares were acquired upon vesting of restricted stock units on September 11-12, 2026. This is a small, routine sale by a director to cover tax obligations from RSU vesting, not a discretionary insider sale.

Key Facts

  • Director Berndt Modig filed Form 144 to sell 2,291 shares of Pharvaris N.V. common stock.
  • Estimated sale value: approximately $87,104 (based on ~$38.02/share).
  • Shares were acquired upon vesting of restricted stock units on September 11-12, 2026.
  • The sale is part of a pre-arranged 10b5-1 plan, with prior sales in June, July, and August 2026 of similar size.
  • The filing represents intent to sell; the actual sale may not occur.

Financial Impact

~$87,000 sale by a director, representing a tiny fraction of the $2.6B market cap.

dilution

Risk Factors

  • Form 144 is only an intent to sell; the actual sale may not execute.
  • If the stock declines, the insider may choose not to sell at the lower price.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-009440
Document: 0001950047-26-009440-index.html0001950047-26-009440
Document: 0001950047-26-009440.txt0001950047-26-009440
37 reports for PHVS
Performance horizon
90% Hit rate 9 of 10 directional calls best @ T+60▲ +21.31%Mar 20, 2026
Filters
Rows
Reports for PHVS — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$38.06 $36.37▲ +4.44%▲ +5.26%$31.07 (+18.38%)
Sep 14, 2026
17d ago
144
NEUTRAL ★ 2/10
$38.06 $35.20▼ −7.51%▼ −9.63%$31.07 (−18.38%)
Sep 14, 2026
18d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.86 $36.02▼ −7.31%▼ −7.41%$31.07 (−20.06%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$38.02 $36.37▼ −4.34%▼ −4.12%$31.07 (−18.29%)
Sep 8, 2026
24d ago
6-K
BULLISH ★ 8/10
$37.84 $38.86▲ +2.70%▲ +3.36%$31.07 (−17.90%)
Aug 12, 2026
7w ago
6-K
NEUTRAL ★ 6/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 12, 2026
7w ago
Press Release
BULLISH ★ 7/10
$36.46 $36.27▼ −0.52%▼ −0.08%$31.07 (−14.80%)
Aug 6, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$34.45 $34.04▼ −1.19%▼ −2.40%$31.07 (−9.83%)
Jul 6, 2026
12w ago
Press Release
BULLISH ★ 6/10
$33.22 $35.07▲ +5.57%▲ +5.08%$31.07 (−6.49%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$33.86 $35.96▲ +6.20%▲ +5.27%$31.07 (−8.25%)
Showing 10 of 37

US Market Status

Market Open — Closes in 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access